Congress trades and big insider sales, sent the day they're filed. Free.
Open in TelegramChief Scientific OfficerCIK 0001817160
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 11 | Hansen GwennChief Scientific Officer |  NRIXNurix Therapeutics, Inc.Open-market sale · 10b5-1 plan | SELL | $104K 3,957 sh | Nov 2, 2026 traded Oct 30, 2026 | |
Hansen GwennChief Scientific Officer |
| NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan |
| M |
| $2,701 1,452 sh |
| Nov 2, 2026 traded Nov 2, 2026 |
| 8 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $39K 1,452 sh | Nov 2, 2026 traded Nov 2, 2026 |
| 0 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 3,750 sh | Nov 2, 2026 traded Oct 30, 2026 |
| 0 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 3,573 sh | Nov 2, 2026 traded Oct 30, 2026 |
| 0 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 1,452 sh | Nov 2, 2026 traded Nov 2, 2026 |
| 0 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 2,859 sh | Nov 2, 2026 traded Oct 30, 2026 |
| 0 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 3,573 sh | Nov 2, 2026 traded Oct 30, 2026 |
| 0 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 2,859 sh | Nov 2, 2026 traded Oct 30, 2026 |
| 4 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 3,750 sh | Nov 2, 2026 traded Oct 30, 2026 |
| 0 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $2,701 1,452 sh | Oct 15, 2026 traded Oct 15, 2026 |
| 1 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $36K 1,452 sh | Oct 15, 2026 traded Oct 15, 2026 |
| 0 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 1,452 sh | Oct 15, 2026 traded Oct 15, 2026 |
| 0 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 1,452 sh | Sep 1, 2026 traded Sep 1, 2026 |
| 0 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $2,701 1,452 sh | Sep 1, 2026 traded Sep 1, 2026 |
| 1 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $37K 1,452 sh | Sep 1, 2026 traded Sep 1, 2026 |
| 9 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $108K 5,394 sh | Jun 25, 2026 traded Jun 25, 2026 |
| 5 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,858 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 5 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,750 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 9 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,858 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 30 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Open-market sale | SELL | $53K 3,214 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 13 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,750 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 5 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,000 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 5 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,000 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 17 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,750 sh | Jan 30, 2026 traded Jan 30, 2026 |
| 38 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Open-market sale | SELL | $80K 4,797 sh | Jan 30, 2026 traded Jan 30, 2026 |
| 9 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,859 sh | Jan 30, 2026 traded Jan 30, 2026 |
| 9 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,000 sh | Jan 30, 2026 traded Jan 30, 2026 |
| 9 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,750 sh | Jan 30, 2026 traded Jan 30, 2026 |
| 9 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,207 sh | Jan 30, 2026 traded Jan 30, 2026 |
| 13 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,859 sh | Jan 30, 2026 traded Jan 30, 2026 |
| 9 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,000 sh | Jan 30, 2026 traded Jan 30, 2026 |
| 9 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,207 sh | Jan 30, 2026 traded Jan 30, 2026 |
| 31 | Hansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Open-market sale | SELL | $1,702 98 sh | Jan 30, 2026 traded Jan 30, 2026 |